Light Street Capital Management LLC Reduces Stock Position in Cellebrite DI Ltd. $CLBT

Light Street Capital Management LLC decreased its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 35.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 357,755 shares of the company’s stock after selling 195,000 shares during the period. Cellebrite DI makes up about 1.1% of Light Street Capital Management LLC’s holdings, making the stock its 20th largest holding. Light Street Capital Management LLC’s holdings in Cellebrite DI were worth $6,629,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Financial Management Professionals Inc. acquired a new stake in shares of Cellebrite DI during the 3rd quarter worth about $28,000. CWM LLC raised its position in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after buying an additional 720 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Cellebrite DI by 1,998.0% in the second quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after buying an additional 1,998 shares during the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Cellebrite DI during the third quarter valued at approximately $38,000. Finally, Pacer Advisors Inc. lifted its stake in shares of Cellebrite DI by 523.4% during the third quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock valued at $51,000 after buying an additional 2,303 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Finally, Needham & Company LLC decreased their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $14.40 on Tuesday. The firm has a market cap of $3.59 billion, a P/E ratio of 46.45, a PEG ratio of 2.21 and a beta of 1.30. Cellebrite DI Ltd. has a 1-year low of $11.76 and a 1-year high of $20.86. The firm’s 50-day simple moving average is $15.19 and its 200-day simple moving average is $16.89.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.14. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The business had revenue of $128.82 million for the quarter, compared to analysts’ expectations of $126.07 million. During the same period last year, the company earned $0.10 earnings per share. The company’s quarterly revenue was up 28.8% on a year-over-year basis. Analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.